@article{Sancini2016, 
author = {Giulio Sancini and Roberta Dal Magro and Francesca Ornaghi and Claudia Balducci and Gianluigi Forloni and Marco Gobbi and Mario Salmona and Francesca Re},
title = {Pulmonary administration of functionalized nanoparticles significantly reduces beta-amyloid in the brain of an Alzheimer's disease murine model},
year = {2016},
journal = {Nano Research},
volume = {9},
number = {7},
pages = {2190-2201},
keywords = {ApoE-derived peptide, lung administration, nanoparticles, Alzheimer's disease, liposomes},
url = {https://www.sciopen.com/article/10.1007/s12274-016-1108-8},
doi = {10.1007/s12274-016-1108-8},
abstract = {Treatment options for Alzheimer's disease (AD) are limited because of the inability of drugs to cross the blood-brain barrier (BBB). A promising strategy to overcome this obstacle is the use of nanoparticles (NPs). Previously, we showed that intraperitoneal administration of liposomes functionalized with phosphatidic acid and an ApoE-derived peptide (mApoE-PA-LIP) reduces brain beta-amyloid (Aβ) burden and ameliorates impaired memory in AD mice. Here, we investigated lung administration as an alternative, non-invasive NP delivery route for reaching the brain. Our results show that mApoE-PA-LIP were able to cross the pulmonary epithelium ([14C]-PA permeability = 6.5 ± 2.0 × 10-6 cm/min) in vitro and reach the brain (up to 0.6 μg PA/g brain) following in vivo intratracheal instillations. Lung administration of mApoE-PA-LIP to AD mice significantly decreased total brain Aβ (-60%; p &lt; 0.05) compared to untreated mice. These results suggest that pulmonary administration could be exploited for brain delivery of NPs designed for AD therapy.}
}